Patents by Inventor Aurelia Conte

Aurelia Conte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132522
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 25, 2024
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Aurelia CONTE, Jiyun CHEN, Son Minh PHAM
  • Patent number: 9809599
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: November 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
  • Patent number: 9708340
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: July 18, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Patent number: 9562052
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, A1, A2, A3, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Publication number: 20160185795
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 16, 2015
    Publication date: June 30, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
  • Patent number: 9278918
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 8, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Publication number: 20160060270
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.
    Type: Application
    Filed: November 11, 2015
    Publication date: March 3, 2016
    Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
  • Publication number: 20160002152
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
  • Publication number: 20150368256
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, A1, A2, A3, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: February 20, 2015
    Publication date: December 24, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Bernd Buettelmann, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
  • Patent number: 9199938
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: December 1, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
  • Publication number: 20150148363
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • Publication number: 20140005400
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • Patent number: 8552024
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: October 8, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker
  • Patent number: 8501768
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, A, E, G and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used for the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: August 6, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch
  • Patent number: 8497288
    Abstract: The invention provides novel compounds having the general formula (I), wherein R1, R2, R3 and A are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used in the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: July 30, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch
  • Patent number: 8470843
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and A are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: June 25, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • Patent number: 8440710
    Abstract: The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof. The are useful as HSL inhibitors and may, for example, be used in treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, and obesity.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: May 14, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, Stephan Brugger, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • Patent number: 8399676
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1, R2, R3 and R4 have the significance given in claim 1.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: March 19, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Stanley Wertheimer
  • Patent number: 8389539
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein R1, R2, R3 and n have the significance given in claim 1.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: March 5, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • Patent number: 8329904
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, m, A, R1 and R2 have the significance given in the description. The compounds are useful as HSL inhibitors and may be used in the treatment or prophylaxis of diabetes, dyslipidemia, atherosclerosis or obesity.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: December 11, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer